AAA to support University of Lausanne Hospitals

The University of Lausanne Hospitals (CHUV) will participate in a study on the impact of F-18 Fluorocholine PET/CT and MR Imaging/Spectroscopy in the Management of primary and recurrent prostate cancer. The sponsors and collaborators of this study are AAA and the Centre d’Imagerie Biomédicale (CIBM) in Lausanne. This study will run in parallel to the work-up of primary prostate cancer, as the F-Choline radiopharmaceutical will be available during the time of study at absolutely no cost to patients or CHUV. A number of studies have demonstrated the benefits of F-18 FCH PET/CT for these patients and this indication is currently not reimbursed by the Swiss obligatory health insurance providers.

GiPharma acquires a new licence in France

Gipharma was recently granted marketing authorization in France for Mibitec, a generic version of the widest used SPECT cardiac imaging agent. Mibitec has approved indications for Myocardial perfusion scintigraphy, detection and localization of coronary artery disease and myocardial infarction, assessment of global ventricular function, detection of suspected breast cancer, and localization of hyper-functioning parathyroid tissue.

AAA enters SNM Clinical Trials Network

Advanced Accelerator Applications, Erigal Limited and IBA Molecular – all European suppliers of radiopharmaceuticals used in PET imaging – have signed up to the SNM Clinical Trials Network, which currently has 201 affiliated PET manufacturing sites globally. The network is an initiative designed to address the need for streamlined drug discovery through the integration of imaging biomarkers into multicenter clinical trials. It also gained investigational new drug status for using fluorothymidine in its multicenter trials.

AAA strengthens the collaborations with Université de la Méditerranée

June 25th, 2009 – AAA signed today a new collaboration agreement with the Marseille-based Université de la Mediterranée after winning the tender for the construction of a production and R&D laboratory in 2008. According to the agreement, AAA will act as a private company hosted in the CERIMED – European Centre for Research in Medical Imaging – premises for the production and sale of radiotracers in France and abroad. AAA will also become one of CERIMED’s privileged partners for the research and development of new radiopharmaceuticals, as well as for the commercial exploitation. The construction of the production and R&D site, which will host three radiopharmaceutical laboratories and two cyclotrons, should start in October 2010, and should be operational and ready for sales at the end of 2011. Headquartered in Marseille, CERIMED is a project aiming at a European centre of excellence for the development of molecular imaging technologies to promote a multidisciplinary community working in the field of medical imaging.

Maurizio Mariani is the new Head of R&D

April 2nd, 2009 – AAA announces today that Dr. Maurizio Mariani joined the group as the new Head of R&D. Prior to joining AAA, Dr. Maurizio Mariani held the position of General Manager of Merck Serono RBM S.p.A. (Colleretto Giacosa, Italy) and of Head Exploratory Medicine for the Merck Serono Group (Geneva, Switzerland). Dr. Mariani holds a degree in Medicine and Surgery from La Sapienza University, Rome, Italy and a PhD in Pharmacology from Temple University, Philadelphia, United States. In 1991 he obtained the Diploma of the American Board of Toxicology (DABT). Dr. Mariani has a long experience in pharmaceutical research and development.

AAA to manage THERANEAN project with Lyonbiopôle

March 26th, 2009 – Following the 7th Call for Projects of the Single Inter-Ministry Fund (FUI) in 2008, Lyonbiopôle obtained funding for four new R&D projects from various companies, including the THERANEAN (THERApy through NEutron Activation using Nanoparticles) R&D project. The objective of the THERANEAN project is the development and pre-clinical validation of a methodology for solid tumors therapy. This methodology is based on the use of sub-micrometric/nano particles charged with beta/gamma emitters produced in a cyclotron-driven neutron activator. AAA is the project leader together with CERMA, Centre d’Etude et de Recherche Médicale d’Archamps, and other universities and research centers.

AAA Italy gets the authorizations to handle transportations

AAA Italy obtained all the necessary authorizations to transport by road radioactive materials in Italy. The company will achieve approximately a € 60 cost saving for every transport, as it will no longer have to pay a commission to other companies for the use of their transport authorization. The annual costs savings will be well beyond €100,000.

AAA acquires Italian pharma manufacturer GiPharma

JAAA acquires Italian pharma manufacturer GiPharmanuary 27th, 2009 – AAA Italy has completed the acquisition of Gipharma , a pharmaceutical contract manufacturer for injectable and freeze-dried products, specialized in radiopharmaceuticals (RP) for SPECT. Gipharma was founded in 2002 and is based in the Saluggia (VC) Technological Park. Thanks to this acquisition, AAA will increase its presence in the SPECT market – which accounts today for the 70% of the global nuclear medicine business and shows positive growth perspectives in the coming years. Gipharma also offers a wide range of custom manufacturing and analytical services under cGMP requirements.